Recent News

• 02.20.2025 - Unicycive Therapeutics Announces the Publication of Preclinical Data on Synergies Between Oxylanthanum Carbonate and Tenapanor in American Society of Nephrology Journal Kidney360
• 02.06.2025 - Video: An Unmet Need in Hyperphosphatemia
• 02.06.2025 - Video: OLC Pipeline
• 02.06.2025 - Video: Our Purpose
• 02.06.2025 - Video: About Unicycive
• 02.05.2025 - Effects of Oxylanthanum Carbonate in Patients Receiving Maintenance Hemodialysis with Hyperphosphatemia
• 02.05.2025 - Effects of Oxylanthanum Carbonate in Patients Receiving Maintenance Hemodialysis with Hyperphosphatemia
• 02.04.2025 - Video: Interview with Dr. Glenn Chertow
• 01.28.2025 - Unicycive Therapeutics Announces the Publication of Patient Perspectives on Phosphate Management in the Journal of Nephrological Science
• 01.07.2025 - Unicycive Therapeutics Announces Publication of Positive Oxylanthanum Carbonate (OLC) Dose Escalation Data in Clinical and Translational Science

Recent Filings

• 02.19.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.14.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.06.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 01.07.2025 - 8-K Current report
• 12.20.2024 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 12.20.2024 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 11.20.2024 - EFFECT Notice of Effectiveness